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Abstract
This article discusses the use of cryotherapy for the treatment of hepatic tumours, from its early origins to the present day.
Results of therapy, preoperative assessment, safety, and the pros and cons of its use are described.
Introduction
Cryotherapy is a rather more mature ablative
technique than radiofrequency ablation (RFA), and
was started in earnest using coaxial insulated probes
under ultrasound control by a few groups in the
late 1980s [1]. However, its origins stem back over
one and a half centuries to Arnott [2], when it was
used as a means of local pain control and haemostasis
in cancer.
Over 2100 patients had received hepatic cryother-
apy in a world survey conducted in 1999 [3], with the
largest response from the United States. Our own
experience over the last 12 years is 172 patients
treated with hepatic cryotherapy. This time and effort
should now provide us with some useful data with
which to measure its value.
Applications and results
The use of cryotherapy to completely ablate
unresectable liver metastases is perhaps the central
issue regarding its role in the surgeon’s tool box.
Our definition of unresectable lesions encompasses
multiple (more than five lesions) bilobar disease that
is beyond the scope of multiple segmental resections
to achieve total clearance.
We recently reported long-term survival data from
our series of 146 patients following cryotherapy with
or without resection, for colorectal metastases. At 1,
2, 3, 4 and 5 years survival rates were 89%, 65%,
41%, 24% and 19%, respectively. Perhaps the most
fundamental issue was that 25% of patients with six or
seven lesions, who might not have been offered this
option by many groups, were alive at 5 years (Table I)
[4]. The use of cryotherapy is not, in this group’s view,
a palliative procedure: the aim of the therapy is
complete tumour eradication with at least 1 cm
clearance, which we have achieved in 78% of patients.
Other units have similarly reported the marked
difference in survival in those patients in whom
complete tumour ablation was achieved [57].
Standard preoperative assessment of patients
includes computed tomography (CT) scans of the
chest, abdomen and pelvis, and bone scan. This is
followed by CT portography in patients in whom
extrahepatic disease is excluded.
The number of lesions clearly must be of some
importance, but in the select group of patients with no
extrahepatic disease and where we were successful in
completely destroying all liver disease, the number of
hepatic lesions was not prognostic.
However, the diameter of lesions is highly prog-
nostic for local recurrence, and our disappointing
early results with lesions /3 cm led to a change in our
approach to resect larger lesions wherever possible,
which has already resulted in a much lower local
recurrence rate. Both preoperataive and postoperative
carcinoembryonic antigen (CEA) levels are also highly
prognostic for long-term survival. In our series, raised
postoperative CEA was highly prognostic for disease-
free intervals of the cryotherapy sites, the remaining
liver, and the extrahepatic sites, as well as overall
disease-free interval [4].
While this group would still not advocate cryother-
apy for resectable disease in a non-cirrhotic liver, the
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randomized trial by Korpan [8] suggests that quite
similar survival results may be achieved. The 3-,
5- and 10-year survival rates for the cryotherapy
group were 60%, 44% and 10%, respectively, whereas
those for the resection group were 51%, 36% and 5%,
respectively. Despite being strong proponents of
cryotherapy, we do not believe that the operative
mortality rates of cryotherapy and liver resection are
different.
The safety of cryotherapy compared with RFA is a
controversial issue, clouded by the fact that many
RFA series have been done percutaneously, and
almost all cryotherapy is done at open laparotomy.
If one compares mortality and morbidity of cryother-
apy and RFA there is little difference [3,9,10].
Intraoperative ultrasound is essential for cryotherapy
and RFA, whatever access route is used. Numerous
studies have demonstrated that intraoperative
ultrasound is capable of identifying hepatic lesions
that are undetectable by preoperative imaging [11,12]
or palpation of the liver itself [13]. The benefit of an
open operation is that the surgeon has the critical
advantage of mobilizing the liver and feeling and
seeing lesions in addition to using high frequency
ultrasound, greatly assisting the placement of
RFA probes or cryoprobes.
There is clear evidence from some series that the
recurrence rate after open RFA is much lower than after
percutaneous RFA. In a study comparing open,
percutaneous and laparoscopic RFA, with a median
follow-up of 12 months, Kuvshinoff and Ota reported
ablation site recurrence in only 6% of open procedures
[14]. Laparoscopic and percutaneous RFA had more
deleterious local recurrence rates: 23% and 53%,
respectively.
In patients with six or seven lesions in whom we
have reported a 25% 5-year survival, we wonder how
many of these could have been treated by percuta-
neous RFA. Of course with such a large number of
lesions being treated with cryotherapy, even with
multiple probe placement, duration of these proce-
dures is also an issue and RFA would be much slower.
We have used cryotherapy to treat the contralateral
side of the liver at the time of resection, and reported
no difference in survival compared to resection alone
at 3 years in 117 patients [15]. Our patients who
have had cryotherapy at the time of their resection
currently have a 30% 5-year survival.
We have used cryotherapy to treat an involved
or close (B/1 cm) edge of resection margins for
colorectal metastases in 110 patients. At a median
follow-up of 70.43 months, 49 patients (66%) had
liver recurrence, with only 8 patients with local edge
recurrence following edge cryotherapy [16]. The
median survival for patients with an involved margin
was 32.3 months and for a close margin was 39.3
months. The demonstration of a 5-year survival of
25% in patients with an involved resection margin is
significant in these patients, in that they would have
been expected to die of their inadequate resection.
The pros and cons of cryotherapy
Cryotherapy has some clear advantages over other
common local ablative techniques. First, multiple
probes can be used concurrently, which is important
for limiting the time of these procedures. Unipolar
RFA systems simply cannot use multiple probes
simultaneously, although bipolar probes might be
able to do so in the future. The most important
difference between RFA and cryotherapy, at least
in our health system, is that cryoprobes can be
re-sterilized and used for many years. We believe
that the ability to feel, image and accurately place
probes in lesions is considerably easier at open
operation. The edges of cryoablated lesions are very
clearly demarcated from normal tissue on ultrasound,
and allow for continuous monitoring of the iceball if
necessary.
The disadvantages of cryotherapy include the
diameter of probes (minimum 3.5 mm for a liquid
nitrogen system), which essentially precludes
percutaneous use. Cracking of cryolesions does occur
frequently, accounting for 8% of cryotherapy-
associated morbidity [3], and can cause consid-
erable bleeding. We control this quite easily with
Table I. Survival figures for cryotherapy of liver lesions demonstrating comparable survival for cryotherapy used with liver resection and the




Operation type 1-year 2-year 3-year 4-year 5-year
Cryotherapy alone 92 85 57 32 21 13
Cryotherapy and liver resection 80 85 66 42 19 19
Number of cryotreated lesions
12 97 87 61 38 21 17
36 66 85 62 33 17 11
79 9 67 44 33 33 22
Completeness of ablation
Yes 146 89 65 41 24 19
No 26 65 38 13 8 0
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compression and a figure-of-eight suture if needed.
More substantial haemorrhage is uncommon and
is more usually associated with incomplete thawing
of the cryolesion prior to closing the abdomen.
However, the subsequent postoperative bleeding
from this and other causes following cryotherapy is
comparable to that of liver resection.
Cryoshock is a cytokine-mediated complication
characterized by varying degrees of severe coagu-
lopathy, disseminated intravascular coagulation
(DIC) and multi-organ failure. It is causally asso-
ciated with complete thaw prior to refreezing and
double freeze cycles [17], as well as volume of
cryotherapy. The underlying mechanism of cryoshock
has not been completely elucidated, although it
appears to be related to post-cryotherapy circulating
inflammatory mediators, of which interleukin-6
(IL-6) and tumour necrosis factor-a (TNF-a) are
the most important [18].
As previously mentioned, we practise a partial
double freeze thaw process and as such have not lost
a patient to cryoshock [3], although the world
literature indicates that cryoshock affects 1% of
cryotherapy patients.
Conclusions
Since its implementation, cryotherapy has matured
in a number of ways and as a result we have
changed aspects of our use of cryotherapy for liver
lesions. The most pertinent of these changes are listed
below.
1. Only complete cryotherapy offers long-term
survival. We have demonstrated on numerous
occasions that incomplete cryotherapy greatly
affects the potential benefit that can be achieved.
2. The best results for cryotherapy consistently
seem to be for lesions 5/3 cm in diameter.
3. Intraoperative ultrasound would be advocated
by our department as a means of assessing
cryotherapy margins in real time.
4. The Pringle manoeuvre during cryotherapy
effects a more rapid and thorough iceball,
especially when the lesion is adjacent to large
vessels.
5. The utilization of a partial double freeze thaw
technique instead of the previously described
complete double freeze thaw, might confer a
safety benefit without any appreciable loss in
efficacy.
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